In this algorithm the use of the word depression refers to the PHQ-9screening scale and not to a clinical diagnosis 1. Initial diagnosis/start of treatment, regular intervals during treatment, 3, 6, and 12 months post treatment, diagnosis of at recurrence or progression, when approaching death and during times of personal transition or re-appraisal such as family crisis (CAPO guideline: "Assessment of Psychosocial Health Care Needs of the Adult Cancer Patient" by Howell et al, 2009; Cancer Care Nova Scotia Distress Management Pathways, draft 2010). 2. Presence of symptom in the last two weeks, rated as follows: 0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day. 3. Content of remaining 7 Items: sleep problems, low energy, appetite, low self view, concentration difficulties, motor retardation or agitation, and thoughts of self harm. Note: Reference for PHQ-9 cutoff >8 is Thekkkumpurath et al., (2011). Screening for MDD in CA outpatients. Cancer. If patient reports a score of 0 or 1 If patient reports a score of 2 or 3 Complete 7 remaining PHQ-9 items 3 Moderate Symptomatology (Score 8-14) Identify pertinent history / specific risk factors for depression  History: Prior depressive disorder, with/without prior treatment  History: Familial history of depression, with/without prior treatment  History: Persons with other psychiatric disorders (e.g., GAD), including substance abuse  Recurrent, advanced, or progressive disease  Presence of chronic illness(es) in addition to cancer  Singleton (single not married, widowed, divorced) vs. partnered  Unemployed or lower socioeconomic status  Female gender None/Mild Symptomatology Moderate Symptomatology If at any time there is risk of harm to self and/or to others: If YES > Referral for emergency evaluation; Facilitate safe environment; One-to-one observation; Initiate interventions to reduce risk of harm to self and/or others. (The presence of other symptoms, e.g., psychosis, severe agitation and confusion (delirium), may also warrant emergency evaluation). If NO > Continue with algorithm 2 item PHQ-9 2 : 1) Little interest or pleasure in doing things (anhedonia) 2) Feeling down, depressed or helpless (depressed mood)  Has most depressive symptoms  Symptoms interfere moderately to markedly with functioning  Referral to psychology and/or psychiatry for diagnosis and treatment None/Mild Symptomatology (Score 1-7) Moderate Severe Symotomatology (Score 15-19) Severe Symptomatology (Score 20-27) No Further Screening Moderate Severe Symotomatology Severe Symptomatology  No or minimal symptoms of depression  Effective coping skills and access to social support  Written materials as appropriate  Subthreshold depressive symptoms  Functional impairment from 'mild' to 'moderate'  Seek consultation (psychology or psychiatry) for determination of diagnosis
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Psychological (individual)
 Delivered by licensed mental health professionals using relevant treatment manuals which may include some or all of the following content: cognitive change, behavioral activation, biobehavioral strategies, education, and/or relaxation strategies.  Relapse prevention additions are also important.  Monitor for efficacy.  Behavioral couples' therapy can be considered for people with a regular partner and where the relationship may contribute to the development or maintenance of depression.
Supportive Care Services for All Patients, As Available and Appropriate
Provide education and information (verbal plus any relevant materials) for the patient and family about:  Normalcy of stress in the context of cancer  Specific stress reduction strategies (e.g., progressive muscle relaxation)  Sources of informational support/resources (patient library, reliable internet sites)  Availability of supportive care services (e.g., professionally led groups, informational lectures, volunteer organizations) for the patient and family at the institution or in the community  Availability of financial support (e. 
Follow-up and ongoing re-assessment
It is common for persons with depressive symptoms to lack the motivation necessary to follow through on referrals and/or to comply with treatment recommendations. With this in mind, on a bi-weekly or monthly basis, until symptoms have remitted:  Assess follow-through and compliance with individual or group psychological/psychosocial referrals, as well as satisfaction with these services.  Assess compliance with pharmacologic treatment, patient's concerns about side effects, and satisfaction with the symptom relief..  If compliance is poor, assess and construct a plan to circumvent obstacles to compliance, or discuss alternative interventions that present fewer obstacles.  After 8 weeks of treatment, if symptom reduction and satisfaction with treatment are poor, despite good compliance, alter the treatment course (e.g., add a psychological or pharmacological intervention; change the specific medication; refer to individual psychotherapy if group therapy has not proved helpful).
Moderate Severe to Severe Symptom Level
Screening and Assessment -Anxiety in Adults with Cancer *In this algorithm the use of the word anxiety refers to the GAD-7 scale and not to a clinical diagnosis of anxiety disorder(s).
1. Initial diagnosis/start of treatment, regular intervals during treatment, 3, 6, and 12 months post treatment, diagnosis of at recurrence or progression, when approaching death and during times of personal transition or re-appraisal such as family crisis (CAPO guideline: "Assessment of Psychosocial Health Care Needs of the Adult Cancer Patient" by Howell et al, 2009; Cancer Care Nova Scotia Distress Management Pathways, draft 2010).
2.
Presence of symptom in the last two weeks, rated as follows: 0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day. 
Psychological (individual)
 Delivered by licensed mental health professionals using relevant treatment manuals which may include some or all of the following content: cognitive change, behavioral activation, biobehavioral strategies, education, and/or relaxation strategies.  Relapse prevention additions are also important as GAD is most often chronic.  Monitor for efficacy.
Supportive Care Services for All Patients, As Available and Appropriate
Provide education and information (verbal plus any relevant materials) for the patient and family about:
 Normalcy of stress and anxiety in the context of cancer  Specific stress reduction strategies (e.g., progressive muscle relaxation)  Sources of informational support/resources (patient library, reliable internet sites)  Availability of supportive care services (e.g., professionally led groups, informational lectures, volunteer organizations) for the patient and family at the institution or in the community  Availability of financial support (e.g., accommodations, transportation, health/drug benefits)  Information about signs and symptoms of anxiety disorders and their treatment  Information on sleep hygiene and self-management of fatigue  Information on other non-pharmacological interventions (physical activity, nutrition)
Pharmacological
 SSRIs or anxiolytics with choice informed by side effect profiles, interactions, response, patient age and preference.  Consider interventions with short term duration.  Monitor regularly for adherence, side effects, and adverse events.
Psychosocial (group)
 Structured, professionally led, with topics such as: stress reduction, positive coping (seeking information, problem solving, assertive communication), enhancing social support from friends/family, coping with physical symptoms (e.g., fatigue, sexual dysfunction) and bodily changes.  Consider for care pathway 3 should anxiety symptoms not remit or worsen.
None/Mild Symptoms
Care Pathway 1
Supportive Care and Prevention
Moderate Symptoms
Care Pathway 2
Psychological (group) or Psychosocial
Moderate Severe to Severe Symptoms
Care Pathway 3
Psychological (individual) and/or Psychiatric
Follow-up and ongoing re-assessment
As cautiousness and a tendency to avoid threatening stimuli are cardinal features of anxiety pathology, it is common for persons with symptoms of anxiety to not to follow through on potentially helpful referrals or treatment recommendations. With this in mind, on a monthly basis or until symptoms have subsided:  Assess follow-through and compliance with individual or group psychological/ psychosocial referrals, as well as satisfaction with these services.  Assess compliance with pharmacologic treatment, patient's concerns about side effects, and satisfaction with symptom relief.  Consider tapering the patient from any antidepressant medications if anxiety symptoms are under control and if the primary environmental sources of anxiety are no longer present.  If compliance is poor, assess and construct a plan to circumvent obstacles to compliance, or discuss alternative interventions that present fewer obstacles.
o After 8 weeks of treatment, if symptom reduction and satisfaction with treatment are poor, despite good compliance, alter the treatment course (e.g., add a psychological or pharmacological intervention; change the specific medication; refer to individual psychotherapy if group therapy has not proved helpful). • All patients should be offered specific education about fatigue following treatment (e.g. information about the difference between normal and cancer related fatigue, persistence of fatigue post treatment, and causes and contributing factors).All patients should be offered advice on general strategies that help manage fatigue (e.g., maintaining physical activity) and guidance on self-monitoring of fatigue levels. 
History and Physical
Education and Counseling
Physical Activity
Address all medical and substance-induced treatable contributing factors first (e.g., pain, depression, anxiety, emotional distress, sleep disturbance, nutrition deficit, activity level, anemia, medication side-effects, and comorbidities). See Table 2 for more details.
Psychosocial Interventions
• Cognitive behavioral therapy/behavioral therapy can reduce fatigue in cancer survivors.
• Psycho-educational therapies/educational therapies can reduce fatigue in cancer survivors.
• Survivors should be referred to psychosocial service providers who specialize in cancer and are trained to deliver empiricallybased interventions. Psychosocial resources that address fatigue may also be available through the National Cancer Institute (e.g., Moving Beyond Breast Cancer videos).
Mind-Body Interventions
Pharmacologic Interventions
• Evidence suggests that psychostimulants (e.g., methylphenidate) and other wakefulness agents, eg., modafinil can be effectively used to manage fatigue in patients with advanced disease or those on active treatment. However, there is very limited evidence of their effectiveness in reducing fatigue in patients who are disease free following active treatment, outside of the treatment of obstructive sleep apnea. • Small pilot studies have evaluated the impact of supplements, such as ginseng and vitamin D, for cancer-related fatigue.
However, there is no consistent evidence of their effectiveness.
Ongoing Monitoring and Follow-up
Promote ongoing self-monitoring of fatigue levels as a late or long-term cancer or treatment problem in post-treatment survivors. Some patients may also benefit from interventions described below to treat fatigue. Currently, there are no clear standards to select among these for an individual patient. Further research is needed to establish a strategy for prioritizing, sequencing, and linking the available options. If treated for fatigue, patients should be followed and re-evaluated on a regular basis to determine whether treatment is effective or needs to be reassessed.
Treat Contributing Factors
Interventions for Cancer-Related Fatigue
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PREVENTION AND MANAGEMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN SURVIVORS OF ADULT CANCERS: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE
Clinical Question Recommendation Evidence Rating
What are the optimum prevention approaches in the management of chemotherapy-induced neuropathies in adult cancer survivors?
There are no established agents recommended for the prevention of CIPN in cancer patients undergoing treatment with neurotoxic agents. This is based on the paucity of high-quality, consistent evidence and a balance of benefits versus harms. 
PREVENTION AND MANAGEMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN SURVIVORS OF ADULT CANCERS: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE
Clinical Question Recommendation Evidence Rating
Continued, What are the optimum prevention approaches in the management of chemotherapy-induced neuropathies in adult cancer survivors?
Venlafaxine is not recommended for routine use in clinical practice. While the venlafaxine data supports its potential utility, the data were not strong enough to recommend its use in clinical practice, until additional supporting data become available. 
PREVENTION AND MANAGEMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN SURVIVORS OF ADULT CANCERS: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE
Clinical Question Recommendation Evidence Rating
Continued, What are the optimum treatment approaches in the management of chemotherapyinduced neuropathies in adult cancer survivors?
No recommendations can be made on the use of tricyclic antidepressants. However, based on the limited options that are available for this prominent clinical problem and the demonstrated efficacy of these drugs for other neuropathic pain conditions, it is reasonable to try a tricyclic antidepressant (e.g., nortriptyline or desipramine) in patients suffering from CIPN following a discussion with the patients about the limited scientific evidence for CIPN, potential harms, benefits, cost, and patient preferences.
Type: Evidence-based Balance of benefits and harms Evidence quality: Intermediate Strength of Recommendation: Inconclusive
No recommendations can be made on the use of gabapentin, noting that the available data were limited regarding its efficacy for treating CIPN. However, the panel felt that this agent is reasonable to try for selected patients with CIPN pain given that only a single negative randomized trial for this agent was completed, given the established efficacy of gabapentin and pregabalin for other forms of neuropathic pain, and given the limited CIPN treatment options. Patients should be informed about the limited scientific evidence for CIPN, potential harms, benefits, and costs. 
PREVENTION AND MANAGEMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN SURVIVORS OF ADULT CANCERS: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE
Clinical Question Recommendation Evidence Rating
No recommendations can be made on the use of a topical gel treatment containing baclofen (10 mg), amitriptyline HCL (40 mg), and ketamine (20 mg), noting that a single trial supported that this product did decrease CIPN symptoms. Given the available data, the panel felt that this agent is reasonable to try for selected patients with CIPN pain. Patients should be informed about the limited scientific evidence for the treatment of CIPN, potential harms, benefits, and costs.
Type: Evidence-based Benefits outweigh harms Evidence quality: Intermediate Strength of Recommendation: Inconclusive
